The accumulation of amyloid-beta protein in the cerebral cortex in Alzheimer's disease (AD) is one outcome of proteolytic cleavage of amyloid precursor protein (APP). Aberrant cleavage can occur due to the more than 50 mutations documented in the APP gene that are associated with early-onset Alzheimer's disease. Cleavage by beta- and gamma-secretase (in the amyloidogenic pathway) leads to production of insoluble amyloid-beta and soluble APP-beta proteins. The major beta-secretase enzyme is beta-site APP cleaving enzyme 1 (BACE1), a transmembrane protein that contains two aspartate residues in its active site. Elevated levels of BACE1 have been correlated with late-onset sporadic AD.
Alternative names: aspartyl protease 2 (ASP2), beta-secretase 1, HSPC104, KIAA1149, membrane-associated aspartic protease 2, and memapsin-2.
ELISAs for BACE1 Detection
The BASE1 ELISA Kit is a solid phase sandwich ELISA with two highly specific antibodies; one is precoated on the ELISA plate and the other is HRP-conjugated. This assay can be used to measure human, mouse, or rat BACE1 protein in brain tissue extracts or cultured cell lysates.
Antibodies for BACE1 Detection
The Human BACE1 Antibody products are affinity-purified IgG antibodies that recognize human BACE1 protein. The BACE1 antibodies are raised in rabbit using synthetic peptides and can be applied to Western blot (WB) and immunohistochemical (IHC) detection as well as immunoprecipitation (IP) of human BACE1 protein.
